Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) reached a new 52-week high and low on Thursday . The company traded as low as $38.53 and last traded at $38.32, with a volume of 81455 shares. The stock had previously closed at $37.78.
A number of brokerages have recently issued reports on PTCT. ValuEngine upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 31st. William Blair restated a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, May 10th. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. Barclays lowered shares of PTC Therapeutics from an “equal weight” rating to an “underweight” rating and raised their target price for the stock from $24.00 to $26.00 in a research report on Tuesday, April 3rd. Finally, Citigroup raised their target price on shares of PTC Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $23.86.
The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.16 and a current ratio of 3.33. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -19.00 and a beta of 1.71.
In related news, COO Marcio Souza sold 5,161 shares of PTC Therapeutics stock in a transaction on Friday, June 1st. The shares were sold at an average price of $34.65, for a total value of $178,828.65. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 7.50% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Seven Eight Capital LP purchased a new position in PTC Therapeutics in the 1st quarter valued at $216,000. Chubb Ltd purchased a new position in PTC Therapeutics in the 1st quarter valued at $221,000. Bayesian Capital Management LP purchased a new position in PTC Therapeutics in the 1st quarter valued at $353,000. MANA Advisors LLC purchased a new position in PTC Therapeutics in the 4th quarter valued at $221,000. Finally, Teacher Retirement System of Texas purchased a new position in PTC Therapeutics in the 4th quarter valued at $228,000. Hedge funds and other institutional investors own 91.77% of the company’s stock.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.